secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZIMMER BIOMET HOLDINGS, INC. (ZBH)
CIK:        0001136869
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0000950170-24-012530
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zimmer Biomet Q4 2023 net sales $1.94B (+6.3%), adj EPS $2.20; guides FY24 adj EPS $8.00-$8.15
--------------------------------------------------------------------------------

- Q4 net sales $1.94B (+6.3% reported, +6.1% CC); diluted EPS $2.01, adjusted $2.20.
- Full-year 2023 net sales $7.39B (+6.5% reported, +7.5% CC); adjusted EPS $7.55.
- FY 2024 guidance: constant currency revenue growth 5.0%-6.0%; adjusted diluted EPS $8.00-$8.15.
- FDA closed out Warning Letter for Warsaw North Campus; global restructuring targeting ~$200M run-rate savings by 2025.
- Completed $500M share buyback in Jan 2024; appointed Louis Shapiro to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/zbh-20240208.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-012530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer